Is Nectar Lifesciences a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Nectar Lifesciences Ltd is a average quality company .

Is Nectar Lifesciences undervalued or overvalued?

The key valuation ratios of Nectar Lifesciences Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone .

What is Nectar Lifesciences share price return in the past 10 years?

Nectar Lifesciences Ltd share price has declined -1% annually (CAGR) over the past ten years.

Is Nectar Lifesciences a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Nectar Lifesciences Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

Nectar Lifesciences Ltd - Stock Valuation and Financial Performance

Name: Nectar Lifesciences
Brand: Nectar Lifesciences

BSE: 532649 | NSE: NECLIFE | Pharmaceuticals & Drugs | Small Cap

Place order

Nectar Lifesciences Share Price

₹34.25 0.11 0.32%
as on 03-Dec'24 16:59

10 Year X-Ray of Nectar Lifesciences:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	11.6%	10%	9.7%	9.1%	10.3%	8.2%	1.4%	5.8%	2.6%	6.5%	-
Value Creation Index ⓘ	-0.2	-0.3	-0.3	-0.4	-0.3	-0.4	-0.9	-0.6	-0.8	-0.5	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	1,644	1,676	1,643	1,876	2,785	2,363	1,542	1,668	1,524	1,684	1,679
Sales YoY Gr.	-	2%	-2%	14.1%	48.5%	-15.2%	-34.8%	8.2%	-8.7%	10.5%	-
Adj EPS ⓘ	3	2.4	2.4	2.3	2.1	1.3	-2.5	0.8	-2.6	-0.1	0.5
YoY Gr.	-	-17.6%	-0.4%	-3.7%	-9%	-37.3%	-285.7%	NA	-406%	NA	-
BVPS (₹) ⓘ	41.1	42.6	44.9	47.2	49.3	50.6	47.3	48.5	47.5	47.7	48.1
Adj Net Profit ⓘ	66.2	54.4	54.3	52.2	47.5	29.9	-55.4	18.7	-57.7	-2	11
Cash Flow from Ops. ⓘ	144	169	199	65.1	239	286	21.3	95	133	225	-
Debt/CF from Ops. ⓘ	6.4	5.7	4.4	14.7	3.8	2.7	42.4	9.1	5.7	2.8	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	0.3%	-9.6%	3%	10.5%
Adj EPS ⓘ	-167.9%	-153.2%	NA	NA
BVPSⓘ	1.7%	-0.7%	0.3%	0.4%
Share Price	-1%	22.8%	10.7%	15.8%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	7	5.7	5.5	5.1	4.4	2.7	-5	1.7	-5.4	-0.2	1
Op. Profit Mgn % ⓘ	16.2	14.3	13.6	12.6	9.5	9.2	6.6	9.5	3.6	9	10.4
Net Profit Mgn % ⓘ	4	3.3	3.3	2.8	1.7	1.3	-3.6	1.1	-3.8	-0.1	0.6
Debt to Equity ⓘ	1	1	0.9	0.9	0.8	0.7	0.9	0.8	0.7	0.6	0.1
Working Cap Days ⓘ	285	298	324	292	206	240	330	288	310	272	134
Cash Conv. Cycle ⓘ	134	142	153	133	104	115	132	108	126	109	32

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 1.00%

Debt to equity has declined versus last 3 years average to 0.59

Sales growth is good in last 4 quarters at 10.84%

Sales growth has been subdued in last 3 years 2.99%

Net Profit has been subdued in last 3 years 0.00%

Latest Financials - Nectar Lifesciences Ltd.

	Standalone	Consolidated
TTM EPS (₹)	0.5	0.5
TTM Sales (₹ Cr.)	1,679	1,679
BVPS (₹.) ⓘ	48.1	48.1
Reserves (₹ Cr.) ⓘ	1,055	1,055
P/BV ⓘ	0.71	0.71
PE ⓘ	71.34	71.37

From the Market
52 Week Low / High (₹)	26.20 / 56.39
All Time Low / High (₹)	7.20 / 60.90
Market Cap (₹ Cr.)	766
Equity (₹ Cr.)	22.4
Face Value (₹)	1
Industry PE ⓘ	44.7

Management X-Ray of Nectar Lifesciences:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

100.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Nectar Lifesciences

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Nectar Lifesciences

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	1,644	1,676	1,643	1,876	2,785	2,363	1,542	1,668	1,524	1,684
Operating Expenses ⓘ	1,377	1,437	1,419	1,639	2,521	2,145	1,440	1,509	1,469	1,533
Manufacturing Costs	117	127	129	145	154	140	129	147	173	186
Material Costs	1,141	1,175	1,154	1,366	2,221	1,858	1,156	1,222	1,159	1,202
Employee Cost	59	78	76	75	77	78	71	72	75	82
Other Costs ⓘ	60	57	61	54	69	69	85	68	62	63
Operating Profit ⓘ	267	239	224	236	264	218	102	159	55	152
Operating Profit Margin (%)	16.2%	14.2%	13.6%	12.6%	9.5%	9.2%	6.6%	9.5%	3.6%	9.0%
Other Income ⓘ	20	6	23	6	6	4	11	11	53	24
Interest ⓘ	126	123	117	115	148	126	112	79	89	97
Depreciation ⓘ	77	57	62	64	63	61	60	57	59	61
Exceptional Items ⓘ	0	0	0	0	0	0	-25	0	0	0
Profit Before Tax ⓘ	85	64	67	63	59	36	-85	34	-41	18
Tax ⓘ	18	10	12	10	11	6	-12	9	-18	13
Profit After Tax	66	54	55	52	47	30	-73	25	-22	5
PAT Margin (%)	4.0%	3.2%	3.4%	2.8%	1.7%	1.3%	-4.7%	1.5%	-1.5%	0.3%
Adjusted EPS (₹)	3.0	2.4	2.5	2.3	2.1	1.3	-3.3	1.1	-1.0	0.2
Dividend Payout Ratio (%)	3%	4%	2%	2%	2%	4%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	958	954	1,007	1,059	1,105	1,135	1,061	1,087	1,065	1,069
Share Capital ⓘ	22	22	22	22	22	22	22	22	22	22
Reserves ⓘ	936	932	984	1,036	1,082	1,112	1,038	1,064	1,042	1,047
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	861	873	794	854	802	741	840	794	685	553
Long Term Debt	266	245	164	220	166	121	128	291	226	140
Short Term Debt	595	627	630	634	636	620	712	503	459	412
Trade Payables	456	497	528	539	483	527	342	377	319	420
Others Liabilities ⓘ	236	233	252	272	315	229	132	130	100	142
Total Liabilities ⓘ	2,510	2,557	2,581	2,724	2,704	2,632	2,375	2,387	2,169	2,184
Fixed Assets
Gross Block	1,451	1,384	1,364	1,456	1,490	1,509	1,556	1,563	1,558	1,599
Accumulated Depreciation	518	478	482	604	666	724	784	840	896	957
Net Fixed Assetsⓘ	934	906	881	852	825	785	772	723	662	643
CWIP ⓘ	91	99	102	100	100	115	99	85	78	66
Investmentsⓘ	1	1	1	1	1	1	1	1	1	1
Inventories	791	836	854	859	915	975	587	660	673	709
Trade Receivables	446	492	500	612	561	397	375	447	280	379
Cash Equivalents	33	36	13	9	21	21	25	18	18	20
Others Assetsⓘ	214	186	229	290	282	338	516	454	459	366
Total Assets ⓘ	2,510	2,557	2,581	2,724	2,704	2,632	2,375	2,387	2,169	2,184

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	144	169	199	65	239	286	21	95	133	225
PBT ⓘ	85	65	67	63	59	36	-85	34	-41	18
Adjustment ⓘ	185	174	159	176	207	188	148	125	97	138
Changes in Working Capital ⓘ	-119	-62	-20	-161	-13	72	-39	-65	77	69
Tax Paid ⓘ	-6	-9	-7	-13	-14	-9	-4	0	0	0
Cash Flow From Investing Activity ⓘ	-60	-77	-18	-29	-26	-33	-29	17	52	-17
Capex	-80	-82	-25	-33	-36	-36	-31	15	50	-29
Net Investments	0	-1	0	0	0	0	0	0	1	0
Others ⓘ	21	6	7	3	10	3	3	2	2	12
Cash Flow From Financing Activityⓘ	-61	-89	-204	-40	-201	-252	11	-119	-186	-205
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	0	0	0	-62	-72
Interest Paid ⓘ	-126	-123	-117	-115	-148	-126	-112	-79	-79	-87
Dividend Paid ⓘ	-2	-3	-3	-1	-1	-1	-1	0	0	0
Others ⓘ	66	37	-84	77	-52	-125	125	-41	-44	-47
Net Cash Flow ⓘ	23	3	-24	-4	12	1	4	-8	0	2

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	7.17	5.79	5.62	5.05	4.38	2.68	-6.66	2.36	-2.09	0.47
ROCE (%)	11.58	9.95	9.71	9.12	10.28	8.24	1.41	5.79	2.58	6.54
Asset Turnover Ratio	0.71	0.71	0.68	0.79	1.15	0.99	0.7	0.81	0.77	0.88
PAT to CFO Conversion(x)	2.18	3.13	3.62	1.25	5.09	9.53	N/A	3.8	N/A	45
Working Capital Days
Receivable Days	86	96	104	97	69	66	80	78	76	62
Inventory Days	162	166	177	149	104	131	162	118	139	131
Payable Days	143	148	162	143	84	99	137	107	109	112

Nectar Lifesciences Ltd Stock News

Nectar Lifesciences Ltd FAQs

What is the share price of Nectar Lifesciences?

Company share prices are keep on changing according to the market conditions. The closing price of Nectar Lifesciences on 03-Dec-2024 16:59 is ₹34.25.

What is the market cap of Nectar Lifesciences?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 03-Dec-2024 16:59 the market cap of Nectar Lifesciences stood at ₹765.6.

What is the P/E ratio of Nectar Lifesciences?

The latest P/E ratio of Nectar Lifesciences as of 03-Dec-2024 16:59 is 71.34.

What is the P/B ratio of Nectar Lifesciences?

The latest P/B ratio of Nectar Lifesciences as of 03-Dec-2024 16:59 is 0.71.

What is the 52-week high and low of Nectar Lifesciences?

The 52-week high of Nectar Lifesciences is ₹56.39 and the 52-week low is ₹26.20.

What is the TTM revenue of Nectar Lifesciences?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Nectar Lifesciences is ₹1,679 ( Cr.) .

About Nectar Lifesciences Ltd

Nectar Lifesciences Ltd. (NLL) is a knowledge driven organization which constitutes a vital part of fast growing Indian Pharmaceutical Industry. It has emerged as top ranked organization amongst midsized Pharmaceutical companies in India as per “Fortune Next 500” 2017 & is among top 40 fore runners of the Bio-Pharmaceutical industry in Asia-Pacific Region as per “Bio-Spectrum Asia Pacific” 2016 besides being one of the top amongst Indian API manufacturers.

The company has transformed itself from being a small Domestic API player to one of the most integrated player in the Global Cephalosporins Industry within Anti Infective Therapeutic segment. It currently has a strong hold of API & Formulation business in many countries of the world with various State of Art manufacturing facilities spread across the States of Punjab and Himachal Pradesh with compliance to global standards of cGMP, Environment Health Safety (EHS) as well as pool of thousands of highly skilled, knowledgeable, competent qualified work force at all levels.

Business area of the company

The company has developed fully integrated sustainable production systems to manufacture high quality Cephalosporin intermediates, - Active Pharmaceuticals ingredients (APIs) and Finished Dosage Formulations (FDF or Formulations) to meet the diverse requirements of its customer base in India and over many countries worldwide.

Business segments